Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentJoseph Keane, M. Miles Braun, John Kasznica et al.|New England Journal of Medicine|2001Cited by 3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationS Brown, M. Miles Braun, Mark H. Greene et al.|Arthritis & Rheumatism|2002Cited by 661
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptJong‐Hoon Lee, M. Miles Braun, Nancy R. Slifman et al.|Arthritis & Rheumatism|2002Cited by 448
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agentsNancy R. Slifman, M. Miles Braun, Evelyne T. Edwards et al.|Arthritis & Rheumatism|2003Cited by 387